Research programme: asthma/osteoarthritis therapeutic - CellceutixAlternative Names: KM-278
Latest Information Update: 07 Oct 2015
At a glance
- Originator Cellceutix
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Asthma; Osteoarthritis
Most Recent Events
- 05 Apr 2011 KM 278 is still in Preclinical trials for Asthma and Osteoarthritis in USA